Genomic Medicine Articles & Analysis
43 news found
CD Genomics, a pioneering leader in genomic solutions, is proud to announce its cutting-edge whole genome sequencing (WGS) services. ...
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. ...
"LAA breaks through traditional sequencing constraints, empowering researchers with invaluable insights into the most intricate areas of the genome, accelerating their research and making significant contributions to diverse fields, including cancer research, microbiome studies, and precision medicine." ...
CD Genomics, a leading provider of genomic solutions, has announced a groundbreaking development in genomic research with the introduction of their Full-Length Transcripts Sequencing (Iso-Seq) technology. ...
CD Genomics, a renowned provider of genomics services, is proud to unveil its cutting-edge Whole Exome Sequencing (WES) service. This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era ...
CD Genomics, a leading provider of transcriptomics sequencing solutions, is pleased to announce the launch of its Exosomal RNA Sequencing service. ...
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). ...
Latvian Biotechnology startup Longenesis has partnered with Dante Genomics, a global company of genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants. ...
DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the speaker lineup for its customer presentations at the American Society of Human Genetics (ASHG) 2022 Annual Meeting, which is being held in Los Angeles this week. ...
Michael Blum has co-authored over 50 scientific publications, many of which are the fruit of international collaborations in the fields of population genomics and genomic medicine. Michael holds an engineering degree from Grenoble INP, a PhD in applied mathematics, and completed a post-doctorate in bioinformatics at the University of Michigan. ...
SeqOne Genomics, provider of next-generation genomic analysis solutions for personalized medicine is proud to announce a new strategic partnership with ILC Instrumentos de Laboratório Científicos to facilitate access to its genomic analysis solutions in Portugal. ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date: Thursday, June 9 at 9:00 a.m. ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney ...
Borad, M.D., is currently a Professor of Medicine at Mayo Clinic College of Medicine and Science. He also serves as the Director of the GI Cancer Cellular, Gene and Virus Therapy lab, Director of the Liver and Biliary Cancer Research Program and Co-Director, Precision Cancer Therapeutics Program at the Center for Individualized Medicine at Mayo ...
ByCervoMed
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. ...
The funding will give us the resources we need to enhance and commercialize our solution to make genomic analysis more accessible and affordable so that each patient can benefit from personalized medicine recommendations.” “The genomics analysis market is experiencing exponential growth driven by the needs of personalized ...
(“MNH”) is the world’s leading patient-based AI-functional genomic medical analysis company. MNH is improving human health and accelerating the world’s transition to precision medicine. From completing more than 10,000 in-person patient assessments (hands-on functional medicine and genome-based patient ...
In the United States, the trial was initiated at Weill Cornell Medicine with Dr. Harini Sarva, M.D. as the Principal Investigator and first surgeries being performed by Dr. ...
We continue to view them as a pioneer in the area of genomic medicines and will explore other possible collaboration opportunities as we work together to transition the autologous sickle cell program back to ...